A Clinical Trial to Observe the Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Target Population
NCT ID: NCT07071701
Last Updated: 2025-07-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
19267 participants
OBSERVATIONAL
2022-07-02
2024-04-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine
NCT05477693
Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults and Elderly
NCT02451969
Lot-to-lot Consistency of 23-valent Pneumococcal Polysaccharide Vaccine
NCT05731115
A Clinical Trial to Evaluate the Safety and Immunogenicity of PPV23 Vaccine Revaccinated in 60-70 Years Old
NCT04700618
A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine
NCT04989465
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Acitive safety surveillance group
23-valent pneumococcal polysaccharide vaccine
23-valent pneumococcal polysaccharide vaccine
Influenza vaccine
Influenza vaccine
Passive safety surveillance group
23-valent pneumococcal polysaccharide vaccine
23-valent pneumococcal polysaccharide vaccine
Influenza vaccine
Influenza vaccine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
23-valent pneumococcal polysaccharide vaccine
23-valent pneumococcal polysaccharide vaccine
Influenza vaccine
Influenza vaccine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants and/or their guardians are able to understand and voluntarily participate in this study and sign an informed consent form;
* Provide valid legal identification.
2 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sinovac Biotech Co., Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jiangsu Provincial Center for Disease Prevention and Control
Nanjing, Jiangsu, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRO-PPV-MA4002-JS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.